DENALI THERAPEUTICS INC. - COMMON STOCK

21.93

14-February-25 11:57:38

15 minutes delayed

Stocks

+0.62

+2.91%

Today's range

21.50 - 22.29

ISIN

N/A

Source

NASDAQ

Denali Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to ETV:IDS (DNL310) for the Treatment of Patients with Hunter Syndrome (MPS II)

11 Mar 2021 08:30:00 By Nasdaq GlobeNewswire
Denali Therapeutics Reports Full Year 2020 Financial Results and Business Highlights

25 Feb 2021 16:01:01 By Nasdaq GlobeNewswire
Denali Therapeutics Reports Positive Three-Month Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with Hunter Syndrome (MPS II)

12 Feb 2021 07:30:00 By Nasdaq GlobeNewswire
Denali Therapeutics to Present New Data on ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at WORLDSymposium™

05 Feb 2021 09:00:00 By Nasdaq GlobeNewswire
Denali Therapeutics Announces Appointment of Nancy Thornberry to Board of Directors

11 Jan 2021 08:30:00 By Nasdaq GlobeNewswire
Denali Therapeutics Announces Significant Program Progress and Expected Key Milestones in 2021 for Its Broad Therapeutic Portfolio in Neurodegeneration

08 Jan 2021 08:30:00 By Nasdaq GlobeNewswire

<<
<
1
2
3
4
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.